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Abstract Cell-based implants with or without osteoinductive biomolecules on 
optimal carrier materials as an advanced therapeutic medicinal product (ATMP) are 
a promising strategy for poorly healing long-bone defects. This chapter will focus 
on ATMPs combining bone morphogenetic proteins (BMPs) and progenitor cells 
for the clinical treatment of large bone defects in compromised environments. We 
describe BMP signaling involved in the process of bone fracture healing with spe-
cific emphasis on clinically relevant BMP ligands, followed by characterization and 
BMP responsiveness of progenitor cells obtained from different sources. Then we 
explore different biomaterials and their contribution to achieve optimal BMP release 
and osteoinduction. Finally, we provide a perspective on the applicability of ATMPs 
in bone repair by reviewing the preclinical studies carried out so far in various ani-
mal models. We believe the era of regenerative medicine has just started. First- 
generation BMP and stem cell technologies have demonstrated that in the postnatal 
environment, one can successfully enhance the healing of damaged tissues by reca-
pitulating the principles of developmental tissue formation. A second generation of 
products is needed that leads to successful bone healing in compromised 
environments.
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1  Introduction
Long-bone fractures are most frequently the result of trauma but can also be associ-
ated with a variety of conditions including osteoporosis, infection, tumors, and con-
genital diseases. Moreover, over 10 % of tibia fractures lead to delayed healing or 
nonunion, which greatly affects quality of life for the individual. This patient popu-
lation ultimately demands an effective restoration strategy to fulfill functional 
requirements. Current state of the art for the reconstruction of skeletal defects 
involves transplantation of autologous or allogenic bone grafts, which can be har-
vested from sites such as the iliac crest, fibula, scapula, or radius [189]. However, 
the inherent drawbacks of this approach, including insufficient autologous resources, 
pain, and donor-site morbidity, strongly urge clinicians and researchers to explore 
alternative therapeutic strategies.
Several alternative strategies are emerging to treat nonhealing fractures: (1) a 
“smart” biomaterial device with or without growth factors, which is frequently 
used in non-compromised conditions, and (2) an advanced therapeutic medici-
nal product (ATMP) composed of cell-based implants with or without osteoin-
ductive biomolecules on optimal carrier materials, which is typically targeted 
for use in compromised conditions. The combined factors in such ATMP should 
function synergistically with a potent regenerative effect. Hypothetically, when 
implanted in vivo, they act as a robust engine steering bone formation and integra-
tion, subsequently leading to successful healing of the defect [104]. Indeed, it is 
envisioned that cell-based ATMPs can overcome the limited and defective regen-
erative capacity of the patient. Moreover, in contrast to the single use of growth 
factors which seems to require high doses, the combined cell growth factor ATMP 
is expected to eliminate the necessity of supraphysiological doses of growth factors 
which could potentially induce adverse clinical complications [25]. It is antici-
pated that the soluble growth factors will stimulate proliferation and differentia-
tion of progenitor cells both in carriers and defect site to form new bone tissue. 
Meanwhile, the implanted progenitor cells cross talk with the surrounding tissue 
via the secretion of signaling molecules to accelerate tissue formation, integration, 
and remodeling.
This chapter will focus on ATMPs combining bone morphogenetic proteins 
(BMPs) and stem cells for the clinical treatment of large bone defects in compro-
mised environments. We will describe the BMP signaling that is involved in the 
process of bone fracture healing with specific emphasis on clinically relevant 
BMP ligands, followed by characterization and BMP responsiveness of stem 
cells obtained from different sources. Then we will explore different biomaterials 
and their contribution to achieve optimal BMP release and osteoinduction. 
Finally, we will provide a perspective on the applicability of ATMPs in bone 
repair by reviewing the preclinical studies carried out so far in various animal 
models.
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2  Lessons from Biology: BMP Signaling Involved in Bone 
Healing
2.1   Biological Fundamentals of Bone and Fracture Healing
Bone formation during embryonic development involves three distinct structures 
that generate the skeleton. The somites give rise to the axial skeleton, the lateral 
plate mesoderm generates the limb skeleton and the cranial neural crest gives rise to 
the craniofacial cartilage and bones. Depending on the bone to be formed, two 
major modes of bone formation occur where both involve the transformation of a 
pre-existing mesenchymal tissue into bone tissue. Intramembranous ossification is 
a slow process that involves direct conversion of mesenchymal tissue into bone, 
primarily giving rise to the flat bones of the skull. The second bone-forming pro-
cess, endochondral bone formation, gives rise to the long bones through a process 
where progenitor cells differentiate into cartilage, which subsequently is degraded, 
remodeled, and replaced by bone.
Throughout the life span of an individual, bones continuously undergo remodel-
ing, leading to changes in bone size, shape, and density during growth and load-
induced damage, adapting the bone to an individual’s development. This remodeling 
process is tightly coordinated between bone-forming osteoblasts and bone-resorb-
ing osteoclasts, the latter ones originating from hematopoietic stem cells. The inter-
play between these cells is regulated on both the systemic and local level by 
hormones, cytokines, mechanical signals, and metabolites. Imbalance, upon aging 
or immobilization, between bone formation and resorption, often leads to reduced 
bone density, osteoporosis, and fractures [68].
In healthy individuals, the skeleton acts as a scaffold by providing support and 
protection for the soft tissues that together make up the body. Subsequently, the 
bone has a complex structure and can stand high-impact and mechanical load. 
Fracture occurs upon severe trauma or on minor trauma in diseased bones such as 
osteoporosis. The majority of the fractures can heal spontaneously, due to the high 
regenerative potential of our skeletal system. The healing process, initiated by 
trauma causing the fracture, can be divided in four stages: (1) initial inflammatory 
response and hematoma formation, (2) callus formation, (3) remodeling of callus to 
immature bone, and subsequently (4) remodeling to mature lamellar bone [127]. 
During the initial inflammatory response, cytokines and growth factors are secreted 
by cells at the fracture site to recruit skeletal progenitor cells from mostly the peri-
osteum to aid in the succeeding stages [7]. The nature of secreted stimulatory sig-
nals is partially driven by the type of fracture, hence also which healing process that 
will be initiated.
Fracture healing can occur through two different routes, depending on the 
mechanical stabilization of the fracture: intramembranous (stable fractures) or 
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endochondral (unstable fractures) fracture healing. In the former, osteoblasts 
directly produce and deposit woven bone. This process often takes place in impact 
or compression fractures, where the mechanical stability is high. In more 
 mechanically unstable fractures, bone is formed through an intermediate cartilagi-
nous tissue that can function under hypoxic conditions. The cartilage intermediate 
contributes to stabilization of the fracture, and upon matrix calcification, angiogen-
esis occurs and with new bone formation and remodeling through resorption by 
osteoclasts delivered through the invading blood vessels.
In clinics, over 10 % of annual tibial fractures lead to delayed or nonunions, due 
to the critical size of the defect, severely damaged or infected surrounding tissue, 
and/or genetic disorders [47]. Typically, nonunions can be characterized as hyper-
trophic or atrophic nonunions or a combination of both (Fig. 1) [131] . Hypertrophic 
nonunions are caused by excessive motion at the fracture site, causing abnormal 
vascularity and abundant callus formation, and these can often be successfully 
treated by a stabilizing fixation. Atrophic nonunions are the result of inadequate 
biological conditions, causing fibrous tissue to fill the fracture.
Fig. 1 Long-bone fractures. A fracture of long bones such as tibiae heals spontaneously under 
normal conditions (a). Under specific circumstances, the fracture can develop into an atrophic (b) 
or hypertrophic (c) nonunion (Radiographic images received from Professor, J.  Lammens, UZ 
Leuven, Belgium)
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2.2   BMPs Involved in Bone Development and Fracture 
Healing
Among the different ligands of the BMP family, BMP-2, BMP-4, BMP-5, BMP-6, 
BMP-7, BMP-9, and GDF5 play important roles during bone development and frac-
ture healing. During the early stages of non-compromised endochondral fracture 
healing, BMP-2, BMP-4, BMP-5, BMP-9, and GDF5 can be detected in activated 
periosteal cells and inflammatory cells in the granulation tissue [28]. As the fracture 
healing progresses, the expression level of these signals decreases/fluctuates. The 
proliferating chondrocytes express BMP-2, BMP-6, BMP-7, and BMP-9, while pre- 
hypertrophic chondrocytes express BMP-2, BMP-6, and BMP-7. Once cells have 
differentiated to hypertrophic chondrocytes, they are strongly positive for BMP-2, 
BMP-4, BMP-5, BMP-6, BMP-7, and BMP-9 [28, 222].
While many of the BMP ligands can exert a similar function during fracture heal-
ing as in bone development, some of them seem to play more crucial roles than 
others. For instance, global loss of BMP-2 leads to embryonic lethality [224]. In a 
limb-specific knockout of BMP-2, embryogenesis was not affected but spontaneous 
postnatal fractures occurred that did not heal. These data confirm that other ligands 
cannot compensate for the absence of BMP-2, hence ratifying its crucial role in 
postnatal bone development and fracture repair [196]. In similarity to BMP-2, 
BMP-4 and BMP-7 are present during all stages of bone development and regenera-
tion. However, both have been reported dispensable in these processes in mice [138, 
197, 198].
Nonsense mutations of the BMP-5 gene give rise to a short-ear phenotype 
in mice and lead to reduced plate growth and height as well as body mass [87, 
133]. Upon fracture, these mice display a delayed formation and maturation 
of the cartilaginous fracture callus, only half the volume of healthy fracture 
callus [60].
BMP-6 is highly expressed in the growth plate as well as during the different 
stages of fracture repair. However, the BMP-6 ligand is not crucial for skeletal 
development, maintenance, or fracture healing [59, 100]. Nevertheless, BMP-6 
mutant mice displayed a reduced size of long bones, impaired growth plate func-
tion, and a delayed ossification of the developing sternum [149, 182]. GDF5, another 
member of the BMP family, is found throughout the growth plate of the developing 
long bones, and mutations in this gene have been shown to cause impaired joint 
morphogenesis and brachypodism in mice and man [185, 194]. During fracture 
repair, deletion of GDF5 does not compromise long-term fracture healing, but a 
delay in callus formation and remodeling suggests a role in the early phase of bone 
repair [30]. BMP-9 is mainly known for its regulatory role in angiogenesis, evi-
denced by arteriovenous malformations in BMP-9-deficient mice [155, 218]. 
Interestingly, recent research efforts suggest BMP-9 to be one of the most osteo-
genic ligands, and a first report on skeletal malformations in BMP-9-deficient mice 
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is currently being processed [155]. Moreover, additional support for BMP-9 as an 
interesting osteoinductive factor was evidenced by its role during trauma-induced 
heterotopic ossification [58].
The BMP signaling pathway is strictly regulated; hence, BMP antagonists are 
also present in fluctuating levels during fracture healing. In cartilage- and bone- 
forming cells as well as in granulation tissue, BMP-3, noggin, chordin, gremlin, 
SMAD6, and SMAD7 have been detected [222]. Moreover, BMP ligands and 
receptors, phosphorylated SMAD1/5/8, and BMP inhibitors are also express in non-
unions in similarity to non-compromised fractures [92]. Interestingly, an imbalance 
between the level of ligands and inhibitors was reported with the most striking dif-
ferences in the early cartilaginous tissue intermediates. Potentially, the disrupted 
balance in BMP signaling may be a mechanistic cause of the nonunion (Table 1).
2.3   Current Status of BMPs in Clinical Application
Since the discovery by Marshall Urist of BMPs and their potent bone-inducing 
capacity in 1965, comprehensive research efforts have led to the characterization 
of several ligands from the family. When it comes to bone regenerative medicine 
and the treatment of nonunions, BMP-7 and BMP-2 have gained most attention 
Table 1 The functions of different BMPs during bone development and fracture healing
BMP- Knockout phenotype Fracture healing References
BMP- 2 Embryonically lethal; limb, 
spontaneous fractures and impaired 
fracture repair; chondrocyte, severe 
chondrodysplasia
Expressed during 
inflammatory, chondrogenic, 
and osteogenic stages
[28, 90, 91, 
181, 196, 224]
BMP- 4 Embryonically lethal, limb: 
defective patterning
Expressed during 
chondrogenic and osteogenic 
stages
[28, 90, 91, 
174, 210]
BMP- 5 Short-ear mice, reduced growth 
plate height, growth rate, and body 
mass
Expressed during 
mesenchymal condensation, 
delayed fracture callus 
formation and maturation
[60, 87, 133]
BMP- 6 Delay in sternum ossification, 
smaller long bones
Expressed during 
inflammatory, chondrogenic, 
and osteogenic stages
[28, 149, 182]
BMP- 7 Die after birth, defect in skeletal 
patterning, in limb: no effect
Expressed during 
chondrogenic and osteogenic 
stages
[28, 38, 90, 91, 
119, 171, 198]
BMP- 9 Skeletal malformations, phenotype 
not yet published
Decreased mean levels in 
nonunions
[200]
GDF5 Brachypodism, joint phenotype 
delayed callus formation, and 
remodeling
Expressed during 
chondrogenic stage
[28, 30]
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for a number of reasons including biotech-driven focus. In 2001 and 2002, FDA 
approved the clinical products OP-1® (BMP-7) and Infuse® (BMP-2) for the treat-
ment of long-bone nonunion and anterior lumbar interbody fusions, respectively 
[2, 44]. In the following years, these approvals were extended to posterolateral 
fusion, posterolateral lumbar pseudarthrosis, and nonhealing tibia shaft fractures 
[3–5, 140].
Currently, 11 clinical trials are registered under bone morphogenetic proteins for 
critical bone fractures, one for BMP-7 and the remaining for BMP-2 [71] (Table 2). 
In the majority of these studies, the BMP ligand is delivered through the use of an 
adsorbable collagen sponge (ACS), a calcium phosphate matrix (CPM), or as a 
liquid solution in buffer. The investigated concentrations of BMP-2 are reported 
between 1–12 mg/ml, and the product efficacy in fracture healing was compared to 
autograft or allograft transplants.
Reports from these studies display that approved BMP devices function as an 
alternative treatment, providing similar efficacy as autologous transplants, but does 
not result in an superior outcome [33, 46, 81, 121]. Even though promising, a 
debated therapeutic outcome has been reported due to safety issues and side effects 
possibly related to the usage of supraphysiological doses [49, 187, 211].
2.4   BMP Signaling Pathway
2.4.1  Ligand-Receptor Binding and Oligomerization
When inducing physiological cellular responses, BMP ligands activate intracel-
lular signaling by binding to their respective transmembrane receptors. The active 
receptor complex involves typically one of the type 1 receptors, activin receptor-
like kinase-1 (ALK)1., ALK2, ALK3, or ALK6, and one of the type 2 receptors, 
BMP- receptor type 2 (BMPR2) or activin type 2 receptor (ACVR2 or ACVR2b) 
[178]. It has been reported that BMP-2 and BMP-4 preferentially and predomi-
nantly bind to ALK3 or ALK6, whereas BMP-6 and BMP-7 primarily bind to 
ALK2 [41, 193]. Moreover, BMP ligands bind to type 1 and type 2 receptors with 
different affinities, likely due to their structural conformation [96]. For instance, 
while BMP-2 and BMP-4 bind with high affinity to their type 1 receptor, BMP-7 
binds with high affinity to the type 2 receptors ACVR2a or ACVR2b and less to 
the type 1 receptors [57, 94].
Ligand-receptor oligomerization occurs through two different mechanisms, for-
mation of a pre-formed receptor complex (PRC) or a BMP-induced receptor com-
plex (BRC), causing distinct downstream signaling mechanisms [139]. PRC induces 
signaling through the SMAD-dependent signaling pathway, while BRC-induced 
signaling activates the (mitogen-activated protein kinases) MAPK pathway (Fig. 2). 
The difference in downstream signaling, induced by the oligomerization mecha-
nism, has been explained by two different endocytosis routes, clathrin dependent or 
independent [54, 69, 139].
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2.4.2  SMAD-Dependent Signaling During Bone Formation
The SMAD-dependent signaling cascade is initiated, as the constitutively active 
type 2 receptor phosphorylates the (glycine-serine rich) GS domain of the type 1 
receptor which subsequently phosphorylates and activates the receptor-regulated 
SMAD1/5/8 complex (Fig. 2) [165]. These SMADs commonly consist of a DNA- 
binding domain at the N-terminus and a protein-protein interaction domain at the 
C-terminus domain, connected through a linker domain [83]. Upon phosphorylation 
of the C-terminus domain by the common mediator SMAD4, the R-SMAD com-
plex is formed and translocates to the nucleus where it regulates the expression of 
BMP-responsive genes [97, 118, 165, 180].
The downstream signaling cascade of the R-SMADs can be modulated by phos-
phorylation of the linker region by other cellular kinases such as MAPKs and gly-
cogen synthase kinase 3-beta (GSK-β). These compete with the receptor-mediated 
phosphorylation for deactivation through proteasomal-mediated degradation [50, 
162]. Further fine-tuning of the signaling cascade is regulated by intracellular medi-
ators such as small C-terminal domain phosphatases (SCP)-1 and SCP-2 and tran-
scriptional cofactor BMP type 2 receptor-associated protein cGMP-dependent 
BMP ligand
SMAD1/5/8
P
PPP
P
P
P
P
R-SMAD
Co-SMAD4
Cytoplasm
Nucleus
TABXIAP
TAK
MKK
MEK
p38 JNK Erk1/2
Id1-3
DLX5
RUNX2
SOX9 ACAN
Co-factors/
inhibitors
OSX
2 21 1
Fig. 2 Schematic view of BMP signal transduction. BMP ligands activate intracellular signaling 
by binding to their related transmembrane type 1 and type 2 receptors. Ligand-receptor oligomer-
ization occurs through two different mechanisms where formation of a preformed receptor com-
plex (PRC) mainly induces signaling through the SMAD-dependent signaling route, while 
BMP-induced receptor complex (BRC) preferentially activates the MAPK pathway
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protein kinase 1 (cGK1) [163, 167]. Ubiquitination is another mode of regulating 
SMAD activity, which can lead to either proteasomal-mediated degradation causing 
repressed signal transduction or protein aggregate formation and regulate cellular 
processes as a potential protective mechanism [168]. SMAD6 and SMAD7 are also 
called inhibitory SMADs (I-SMADs), due to their antagonizing of the activation of 
R- and Co-SMADs. SMAD6 mitigates BMP signaling through competing with 
SMAD4 for complex formation [70]; SMAD7, on the other hand, is recruited to the 
receptor and induces degradation of the type 1 receptor kinase together with 
SMURF1 [40].
2.4.3  SMAD-Independent Signaling During Bone Formation
While the SMAD-dependent BMP signaling pathway is well investigated, less is 
known regarding the SMAD-independent pathways. Upon ligand binding to a pre-
formed complex of the types 1 and 2 receptors, activation on gene transcription 
level occurs through the activation of the MAPK pathway (Fig. 2). MAPKs are 
evolutionary conserved enzymes that convert various extracellular stimuli into dif-
ferent cellular responses during biological processes such as fracture healing. The 
key effector enzymes p38, extracellular signal-regulated kinase (ERK), and c-Jun 
N-terminal kinase 1-3 (JNK) are part of a multistep cascade which is tightly regu-
lated by phosphorylation and dephosphorylation processes [61, 80, 141]. JNK sig-
naling is mainly known for its regulatory role in inflammation, apoptosis, and cell 
migration [136, 195]. The ERK-1 and ERK-2 kinases modulate cell survival, prolif-
eration, and differentiation as well as protein synthesis in multiple cell lineages 
[144, 216]. Altered ERK-1/ERK-2 signaling is found in several genetic diseases 
with skeletal phenotypes such as neurofibromatosis type 1, suggesting a role in the 
regulation of skeletal development [9]. BMP-induced ERK signaling occurs through 
MEK1 activation, subsequently increasing Runx2 stability and transcriptional 
activity [82].
Among the various MAPK subfamilies, p38 kinase has attracted elevated atten-
tion in the last years and has proven essential for skeletogenesis and bone 
homeostasis due to its role in cell proliferation, differentiation, apoptosis, senes-
cence, as well as cytokine production and function [56, 79, 106]. Upon BMP 
receptor phosphorylation, it associates with TAK1, TAB1, and XIAP, leading to 
activation of p38 which translocates to the nucleus [56]. Then, p38 activates tran-
scriptional factors ATF2, c-Jun, or c-Fos to regulate BMP target genes such as 
RUNX2, OSX, OPN, ACAN, and ALP [103]. Each of the pathways has been 
proven of importance, since an effect can be seen upon inhibition, and the system 
is tightly controlled through fine-tuning between the activated MAPK pathways 
[98]. Moreover, cross talk between MAPK and SMAD signaling occurs, since it 
has been shown that TAK1 can modulate the duration and intensity of SMAD sig-
naling [15, 72, 167, 177].
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3  Candidate Cell Types for BMP/Cell-Based ATMPs
As aforementioned, the cells can be a driving force for tissue regeneration in cell- 
based ATMPs. Moreover, the necessity of (stem) cells to be included in the develop-
ment of ATMPs becomes particularly important for fractures in compromised 
conditions, such as severely damaged surrounding tissues, elderly patients with sub-
optimal conditions (e.g., diabetes and osteoporosis), or in young children with con-
genital disease (e.g., neurofibromatosis type 1), which all may lead to poor healing 
of the fracture. In such compromised conditions, the surrounding tissue may not be 
able to efficiently respond to the BMP stimuli. In view of this, it is a potential advan-
tage to pre-seed the scaffold with (stem, progenitor) cells combined with a physio-
logical dose of BMP. From a clinical point of view, it is preferable for cell-based 
ATMPs to have a source of human stem cells that can be derived from a small 
biopsy via a noninvasive initial harvest and can proliferate in large numbers and be 
BMP responsive including proliferate and/or differentiate into the osteochondro-
genic lineage upon BMP exposure [126].
3.1   Bone Marrow Stromal Cells (BMSCs)
Bone marrow, which is composed of the hematopoietic compartment and the 
stroma, is the conventional source to obtain human somatic stromal cells for use in 
regenerative medicine. In the hematopoietic compartment, hematopoietic stem 
cells and committed progenitors of different specific hematopoietic lineages reside. 
In the stroma, stromal cells, accessory cells, extracellular matrix components, and 
soluble factors have been described [77]. Taking the heterogeneous population of 
cells into account, it is of relevance to choose a well-defined and robust methodol-
ogy to isolate, characterize, and study the functionality of the expanded stromal 
cell [45].
3.1.1  Isolation and Expansion
BMSCs are usually isolated by cultivation of cells adherent to plastic and obtained 
from untreated whole bone marrow in the form of bone marrow explant or bone 
marrow filter washout [148]. However, this method may lead to low yield of isola-
tion because a large proportion of erythrocytes reside in the untreated bone marrow 
and their presence may interfere with the initial attachment of BMSCs [6]. An alter-
native method to isolate BMSCs is through an initial isolation of mononuclear cells 
by a Ficoll-Hypaque gradient before further cultivation [45]. By removing the 
unwanted high-density blood cells, this method is helpful to increase the number of 
colony-forming unit (CFU) in the primary BMSC culture [6].
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The isolated BMSCs are usually cultured for expansion in basal medium supple-
mented with irradiated fetal bovine serum (FBS) [105]. FBS batches may differ 
from one to another, which could deeply affect the proliferation rate, reproducibil-
ity, and consistency of the production process [23]. Furthermore, FBS raises a gen-
eral concern regarding immunological issues due to potential transfer of xenogeneic 
proteins as well as communicable disease such as prion-transmitted bovine spongi-
form encephalopathy, hence, posing potentially a long-term health risk [122]. In 
consequence, the regulatory authorities encourage replacing the FBS with a non- 
xenogeneic alternative, albeit GMP-compliant FBS batches are available and used 
in clinical-grade manufacturing [23].
As an alternative, human platelet lysate (hPL), a blood-derived product prepared 
as a clinical-grade reagent, has drawn attention for BMSC expansion, since it is a 
rich source of growth factors such as platelet-derived growth factor (PDGF), epider-
mal growth factor (EGF), and basic fibroblast growth factor (bFGF)[19]. Previous 
studies revealed that hPL-expanded MSCs have comparable characteristics with 
those cultured in the presence of FBS [16]. Furthermore, hPL increases prolifera-
tion capacity of BMSCs, hence providing more efficient expansion [22]. However, 
also hPL shows important variability in its growth factor content, and a clinical- 
grade preparation poses still concern.
3.1.2  Characterization and BMP Responsiveness
In vitro, BMSCs represent a phenotypically heterogeneous population of cells. 
Fernandez Vallone et al. comprehensively reviewed the current progress on the phe-
notypic characterization of BMSCs using the fluorescence activated-cell sorter 
(FACS) and magnetic separation techniques [45]. Also our results demonstrated that 
primary cultures of human BMSCs are positive for the following markers: Strol-1, 
CD73, CD49, CD105, CD90, CD146, CD147, and lack of expression of CD14, 
CD20, CD34, and CD45. However, the aforementioned marker expression decreases 
during in vitro passaging, in association with the disappearance of multipotency of 
BMSCs [137]. When subjected to appropriate culture conditions, BMSCs readily 
differentiate into the osteoblastic and chondrogenic lineages, which is particularly 
of interest for bone regeneration. Research showed that BMSCs even possess greater 
osteogenic potential than either chondrogenic or adipogenic potential [137]. 
Moreover, their osteogenic potential appeared to be one of the last lineage commit-
ment phenotypes to be lost [137, 188].
The age and skeletal site of harvest of BMSCs can affect their responses to BMP 
exposure. Osyczka et al. [142] assessed BMP-2 responsiveness (100 ng/ml supple-
mented in serum-containing and serum-free medium) of BMSCs harvested from 
adult maxilla, mandible, and iliac crest BMSCs from the same individuals and pedi-
atric iliac crest. Their results showed that adult orofacial BMSCs were more BMP-2 
responsive than iliac crest BMSCs based on higher gene transcripts of alkaline 
phosphatase, osteopontin, and osteogenic transcription factors MSX-2 and Osterix 
in serum-free insulin-containing medium. Pediatric iliac crest BMSCs were more 
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responsive to recombinant human BMP-2 (rhBMP-2) than adult iliac crest BMSCs 
based on higher expression of alkaline phosphatase and osteopontin in serum- 
containing medium [142].
Nevertheless, it is noted that BMPs are relatively inefficient in inducing human 
BMSC to undergo osteogenesis, albeit they are strong inducers for rat and mouse 
BMSCs [143]. It is shown that mouse-derived BMSCs respond to BMP-2, BMP-4, 
BMP-6, BMP-7, and GDF5 and further undergo chondrogenic differentiation [24, 
43, 172, 173]. However, human BMSCs respond in a different way to distinct 
BMPs. Continuous stimulation of BMP-2, -4, or -7 upregulated the osteochondro-
genic gene expression (e.g., NOGGIN, BMP-2, osteopontin) in human BMSCs 
[36]. However, they failed to enhance alkaline phosphatase activity, an indicator of 
osteogenic differentiation [36, 37]. In addition, continuous stimulation of BMP-2 
with relatively high dosage (100 ng/ml) significantly increased human BMSC pro-
liferation [36]. In contrast, short-term BMP-2 stimulation at lower doses (10–
20 ng/ml) is more effective to induce in vitro osteogenic differentiation, evidenced 
by significantly increased gene expression of RUNX2, COLI, ALP, and OCN, as 
well as protein levels of COLI and ALP [36]. It was hypothesized that the impaired 
BMP response of human BMSCs is correlated with the absence of ALK6 expres-
sion [143]. However, the overexpression of ALK6 in human BMSCs had no effect 
on alkaline phosphatase mRNA transcripts, suggesting that the precise relation-
ship between BMP receptor ALK6 and osteoblast-related genes remains to be 
defined [143]. There is limited research focusing on systematic in vivo evaluation 
of cell- based implants combining BMSCs and BMP. Wang et al. [207] reported a 
moderate increase of bone formation when loading BMSCs and BMP on calcium 
phosphate cements subcutaneously implanted in nude rats after 8 weeks, and such 
improved bone formation can be further enhanced by additional low dosage of 
bFGF (50 ng/ml).
3.2   Periosteum-Derived Cells (PDCs)
Anatomically, the periosteum is a thin vascular membrane that covers the external 
surface of the bone except for the articular joint surfaces of the long bones. It serves 
as an attachment site for tendons, ligaments, and muscles and is a rich source of 
blood vessels that deliver 70–80 % of the blood supply to the bone cortex [26]. 
Microscopically, the periosteum is composed of an outer fibrous layer and an inner 
cambium layer. The fibrous layer contains fibroblasts, collagen, and elastin along 
with a nerve and microvascular network [8], while the inner cambium layer consists 
of progenitor cells with the capacity to differentiate into osteoblasts and chondro-
cytes [64, 183].
The osteogenic potential of the periosteum was revealed early in the eighteenth 
century, when the integrity of the periosteum was found crucial to achieve  successful 
fracture healing [39, 102]. Upon fracture, progenitor cells in the periosteum adja-
cent to the fracture undergo extensive expansion and differentiation to form a 
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cartilaginous fracture callus [31]. The cartilaginous callus progressively bridges the 
fractured bone fragments, followed by replacement by the bone, resulting in the 
formation of a hard callus which eventually is remodeled to the original cortical and 
trabecular bone configuration by osteoclasts.
3.2.1  Isolation and Expansion
To isolate periosteal tissue from the patient, a periosteum elevator, shaped like a 
curved chisel, is typically used to cut off the Sharpey’s fibers that anchor the perios-
teum to the bone, hence maintaining the integrity of the periosteum [27]. Periosteum- 
derived cells (PDCs) are then harvested by enzymatic digestion of the tissue or by 
spontaneous cell egression from the biopsy onto plastic cell culture flasks [156].
In culture, PDCs exhibit a fibroblast-like morphology, which is stably main-
tained over several passages [156]. During in vitro expansion, PDCs do not express 
osteogenic and chondrogenic properties; however, they can be induced to differenti-
ate into the osteogenic, chondrogenic, and adipogenic lineage by exposing them to 
specific differentiation medium [34, 156, 202], confirming their multi-lineage 
potential at the single-cell level.
3.2.2  Characterization and BMP Responsiveness
During expansion, over 90 % of human PDCs express CD73, CD90, and CD105 
[156, 202], while lacking the presence of hematopoietic markers such as CD14, 
CD20, CD34, and CD45 (Ji et al. submitted). In addition, it has been reported that 
PDCs express perivascular cell markers, including αSMA [130], CD146 [156], and 
PDGF receptor beta [202], most likely due to their perivascular location [132, 
159]. This concept is further underscored by our recent report that PDC enhanced 
vasculogenesis by adapting a pericyte-like phenotype when they were implanted 
in vivo [202].
Our data show that continuous in vitro stimulation of BMP-2, BMP-4, BMP-6, 
and BMP-9 (100 ng/ml) significantly enhanced the osteochondrogenic differentia-
tion of human PDCs, evidenced by the upregulation of SOX9, ACAN, RUNX2, OSX, 
DLX5, and ID1. Through mRNA transcript analysis, the BMP-induced differentia-
tion could be correlated to the expression of BMP type 1 and type 2 receptors 
Bolander et al., Eur Cell Mater. 2016 Jan 5;31:11-25. PMID: 26728496.
Upon coating onto calcium phosphate (CaP) carriers followed by hPDC seeding 
and 5-week in vivo implantation in nude mice, only BMP-2- and BMP-6-containing 
constructs gave rise to ossicle formation, including cartilage intermediates, trabeculae- 
like structures embedded in bone marrow with a surrounding cortex-like bone struc-
ture. In these ossicles, the implanted human PDCs contributed to 20 % of de novo 
bone (Bolander et al. submitted). Such enhanced in vivo bone formation might be 
correlated with the activation of SMAD-dependent pathway and MAPK pathway 
within hPDCs induced by BMP and Ca2+ exposure (Bolander et al. submitted).
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3.3   Induced Pluripotent Stem Cells (iPSCs)
Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically 
reprogrammed to an embryonic stem cell-like state by being forced to express genes 
and factors important for maintaining the defined properties of embryonic stem 
cells [124]. Since iPSCs can be derived directly from adult tissues, they not only 
bypass the need for embryos, but can be made in a patient-matched manner, which 
means that each individual could have their own pluripotent stem cell line, revealing 
a potential in personalized medicine.
3.3.1  Generation of iPSCs
In 2006, Yamanaka et al. first reported the generation of mouse iPSCs using retrovi-
ral transduction with 24 transcription factors highly expressed in embryonic stem 
(ES) cells [89]. This cluster of genes was gradually reduced to four key genes that 
encode the transcription factors OCT4, SOX2, KLF4, and c-Myc [191]. Shortly 
after the initial reprogramming success in the mouse, Yamanaka et al. [190] reported 
the generation of iPS cells from adult human dermal fibroblasts using a retroviral 
system with the same four factors: OCT3/4, SOX2, KLF4, and c-Myc. Concurrently, 
Yu et al. [219] reported the generation of human iPSCs from human somatic cells 
with lentivirus using a slightly different combination of genes including OCT4, 
SOX2, NANOG, and LIN28. Notably, the conversion from human somatic fibro-
blast to iPSCs is very low, with reported transduction rate from 0.001 to 1  %, 
depending on different vectors and gene combinations [89]. In 2012, Zhou et al. 
[229] reported a detailed protocol for generating human iPSCs from exfoliated renal 
epithelial cells present in urine, which allow a less-invasive and cost-effective sam-
ple harvest procedure and up to 4 % retroviral transduction efficiency.
3.3.2  Characterizations and BMP Responsiveness
Human iPS cells are similar to human ES cells in morphology, proliferation, 
surface antigens, gene expression, epigenetic status of pluripotent cell-specific 
genes, and telomerase activity, with capacity to further differentiate into cell types 
of the three germ layers including teratoma formation. Based on the guideline 
from the International Stem Cell Banking Initiative (ISCBI), Marti et  al. [128] 
published a detailed characterization of iPSCs. In summary, human iPSCs dem-
onstrate the following characteristics: (i) pluripotency – human iPSCs positively 
express human ES cell markers, such as pluripotent markers placental alkaline 
phosphatase (hPLAP); nuclear transcription factors OCT4, NANOG, and SOX2; 
the keratin sulfate antigens Tra-1-60 and Tra-1-81; and the glycolipid antigens 
SSEA3 and SSEA4. (ii) Differentiation  – In vitro, human iPSCs colonies can 
form large aggregates called embryoid bodies (EBs), which should differentiate 
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spontaneously to different cell types derived from the three germ layers (spon-
taneous differentiation) or can be cultured in different substrates with different 
media to favoring differentiation toward a specific lineage (guided differentia-
tion). Furthermore, the iPSCs will proliferate and differentiate in vivo in the tissue 
where they are injected and ultimately form a teratoma that contains multiple tis-
sues from the three primordial germinal layers characterized by specific markers 
[11] (Table 3).
Recently, we reported in collaboration with Tsumaki labs the reprogramming of 
human dermal fibroblast into induced chondrogenic cells (iChon cells) using lenti-
virus system for Klf4, c-Myc, and Sox9 [192]. The iChon cells demonstrated a 
highly hypertrophic differentiation capacity in vitro and direct or indirect contribu-
tion to cartilage and bone formation in vivo [192], which highlights the promise of 
cellular reprogramming for the creation of functional skeletal cells that can be used 
for novel bone healing strategies.
The generation of iPSCs is regulated by multiple types of signaling cascades, 
including those mediated by BMPs. A recent study demonstrated that BMP signal-
ing during the early stage of iPSC induction can induce a set of miRNAs associ-
ated with the mesenchymal-to-epithelial transition (MET), which can accelerate 
the generation of iPSCs [161]. Such enhancement might be mediated by a receptor 
complex consisting of ALK3 and BMPR2, since suppression of ALK3 and BMPR2 
inhibited the generation of iPSCs [161]. Hamasaki et al. [66] recently showed that 
constitutive activation of ALK2 affected both the upregulation of pluripotent 
markers and the downregulation of fibroblastic markers during the early phase of 
iPSC generation, thus resulting in incomplete reprogramming. The role of ALK3 
and ALK6  in the generation of iPSCs in cellular reprogramming still remains 
unknown.
Similar to ES cells, pluripotency and differentiation of iPSCs are also regulated 
by BMPs. However, many studies have highlighted differences between mouse and 
human ES cells regarding the response to extrinsic signals. For instance, Ying et al. 
[217] reported that BMP-4 sustains self-renewal of mouse ES cells by inducing the 
expression of ID genes. In contrast, in human ES cells, BMP-4 has been shown to 
Table 3 Characteristic markers expressed in human iPSCs
Pluripotency hPLAP,
Oct4, Nanog, Sox2
Tra-1-60, Tra-1-81;
SSEA3, SSEA4, SSEA1 (mouse)
Differentiation Endoderm α-1-Fetoprotein
FoxA2
Mesoderm Brachyury (nuclear)
(Muscle-like tissue) α-smooth muscle actin and 
α-sarcomeric actin
(Cartilage-like tissue) Sox9, fibronectin, chondroitin 
sulfate
Ectoderm Pax6, Sox1, Tuj1
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induce specification into the trophoblastic lineage [212], as well as germ cell lin-
eage differentiation [209]. Consistently, Hamasaki et  al. [66] showed that the 
BMP-4 or BMP-7 reduced the colony-forming capacity of iPSCs and directed 
iPSCs into both mesodermal and endodermal lineage. Therefore, we should be very 
careful to interpret the data obtained from mouse iPSCs and to extrapolate the 
results for studies using human cells.
4  Scaffolding Material for BMP Cell-Based ATMPs for Bone 
Regeneration
4.1   Clinical Perspectives of Desired Scaffold Properties
Effective clinical repair of bone defects is highly dependent on mechanical stability 
in the defect site and requires osteogenic cells and osteoinductive growth factors in 
combination with a proper delivery system, conceptualized as the “diamond concept” 
that provides the optimum mechano-biological conditions for bone regeneration 
[53]. The standard clinical practice for fracture immobilization is by using internal 
or external fixators to prevent micro-motion that will lead to scar tissue or cartilage 
formation. This technique is necessary especially when non-load-bearing biomate-
rial is used as the BMP delivery system/scaffold within an ATMP. Alternatively, 
metallic scaffolds with high mechanical strength could play a role in alleviating 
the adverse effects arising from mechanical instability. Although metallic scaffolds 
provide temporary supports to patients to regain immediate mobility, the non-bio-
degradability of the metals has limited its clinical applications. Nevertheless, sig-
nificant research efforts on developing biodegradable metallic scaffolds with high 
mechanical strength are being carried out in order to overcome this limitation [223].
In addition to the mechanical stability aspect, the biodegradation kinetic of a 
biomaterial needs to match the bone formation process, to precisely control the 
release of BMPs, to guide cell differentiation and bone tissue formation, and to 
timely provide free space for blood vessel ingrowth and bone tissue formation. It is 
being suggested that an ideal biomaterial for bone defect repair should be partially 
degraded by 7  weeks and fully degraded around 14  weeks post-implantation, 
slightly depending on the defect nature including defect site, size, and patient 
profile. Moreover, the degradation by-products should not or minimally interfere 
with the activation of BMP signaling, if possible rather enhance the molecular and 
cellular cascade of bone healing. Therefore, the pharmacokinetic profile of a 
 BMP- based ATMP should preferably be sustained over an appropriate period of 
time that matches the bone healing process in accordance to the cell proliferation 
and differentiation and mineralization effects elicited by BMP, instead of long but 
low concentration of BMP release or initial burst release. In fact, a delicate balance 
in concentration of BMP loading onto scaffolds is required. Furthermore, the phar-
macokinetic profile should be specific to BMP ligands (due to different amino acid 
sequences of the BMP subtypes), the type of fracture or the application, host species 
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(different optimal release profiles are required), and implantation site. These factors 
would determine the form of the BMP delivery system conformations (from injec-
tion, micro-/nanoparticles to 3D porous scaffold), formulation (single or composite 
materials), and the type and amount of BMP in use.
Host environment is another crucial factor that needs to be considered thoroughly 
for designing an effective BMP-based ATMP therapy for bone defects, including the 
suitable BMP dosing and the concentration of BMP at the graft site. However, find-
ings from animal studies are not easy to be translated into a clinical protocol as the 
BMP concentration used in animal studies appears to be lower than the dose required 
in patients. Moreover, the host environment is rich in a variety of organic and inor-
ganic molecules that potentially influence the interaction between the biomaterials 
and BMP as well as the BMP bioactivity, such as in vivo temperature and bodily 
fluid pH and osmolarity. Other clinical implications of BMP treatment that require 
careful considerations include the route of administration and BMP antibody forma-
tion (i.e., 38 % of treated patients in some trials).
Ideally, a BMP carrier should (1) be biodegradable or present adequate poros-
ity to allow the formation of an interface with the surrounding biological tissues 
for cell infiltration, vascularization, and new bone formation, (2) possess full bio-
degradability for complete integration of healed bone tissues, (3) provoke some 
mild inflammatory responses to activate the healing process, and (4) protect BMPs 
from deactivation while releasing the protein in a time- and space-controlled way 
to promote bone regeneration. On top of the requirements from the biomaterial’s 
point of view, other stringent criteria for clinical usage include adaptability to the 
wound site, surgical malleability, as well as patient specificity or customization in 
respect to the treatment duration, anatomical geometry of the defect, and vascu-
larity [65]. Lastly, the ATMPs need to be sterile without either loss of material 
integrity or deactivation of BMPs. Therefore, the respective manufacturing pipe-
lines require special production and handling processes that would give rise to 
conveniently sterilizable, surgeon-friendly implants, stable over time with well-
defined storage procedures (long shelf life). By combining manufacturing tech-
nologies, minimal manual intervention in the production pipeline is highly 
preferable for efficient commercial scale-up manufacturing of the respective 
BMP-based ATMPs, an additional criterion that would facilitate approval by regu-
latory agencies.
4.2   Injectable Materials for BMP- and Cell-Based ATMPs
Due to its water solubility, albeit rather poorly soluble, BMPs can be dissolved in 
water-based buffer solutions (e.g., physiological saline) and delivered in vivo sim-
ply via injection. New generation of BMPs is being developed that improve the 
solubility. Local injection is a potential minimally invasive delivery technique for 
treatment of delayed and nonunions, spinal fusion, and acceleration of healing of 
closed fractures. However, injection of BMPs in solution results in burst release of 
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BMP molecules, hence, a rapid clearance from the defect into surrounding tissues 
which reduces the differentiation effect and potentially causes toxicity and hetero-
topic bone formation.
To overcome these potential adverse effects, BMPs are often added into a protein 
carrier for precise injection into the defect to ensure sustainable BMP release to 
enhance long duration of local-acting differentiation effects. Besides maintaining 
the local BMP concentration, the carriers also provide protection to BMPs from 
deactivation by harmful conditions such as endogenous enzyme digestion and pro-
tein denaturation due to pH shifts. For this, collagen is often used as BMP delivery 
vehicle because it is easy to prepare in an injectable hydrogel form and can be 
obtained as purified recombinant human collagens that are free of animal compo-
nents from reliable and chemically defined sources. Moreover, the binding affinity 
of BMPs to collagen can be modulated by changing the pH or isoelectric point of 
the two proteins in order to obtain specific BMP-release profiles to enhance bone 
formation [52]. Alternatively, gelatin is a cost-effective collagen-derived protein 
carrier that could provide controlled BMP release, by changing the electrical nature 
of gelatin via acidic or alkaline preparation process of collagen. In fact, delivery of 
BMP using collagen or gelatin as carriers showed increased retention ranging from 
15 to 55 % as compared to less than 5 % of BMP dose remaining at the application 
site when no carrier was used [73].
Furthermore, the BMP release and bioactivity can be modulated by varying the 
extent [213] or employing site-specific enzymatic cross-linking of BMP onto gela-
tin [101]. Hyaluronic acid, a natural extracellular matrix (ECM), has been used as 
an effective injectable control release system to augment bone formation due to its 
specific chemical structures that allow chemical modification to ease cross-linking 
and for covalent binding of BMPs [129]. Self-assembly silk fibroin is another inter-
esting injectable BMP hydrogel due to its processing flexibility, biodegradability, 
biocompatibility, and high mechanical toughness. The BMP release can be tailored 
by adjusting the enzymatic degradability of silk fibroin via the control of the crystal-
line state, molecular weight, and secondary structure [150, 157, 226]. Other natural- 
origin biopolymers that are used as injectable BMP hydrogel include alginate [18, 
76], fibrin [145, 214], chitosan/chitin [184], and heparin [107]. Several studies 
showed that the composites of the above mentioned biopolymers either simply by 
mixing two biopolymers [147] or by conjugation [e.g., heparin-conjugated fibrin 
[215] provided more sustainable BMP release and improved in vivo bone regenera-
tion as compared to using collagen alone as a carrier.
Synthetic polymers offer an advantage over the natural-origin biopolymers of 
being free from the risk of disease transmission. These polymer carriers are biode-
gradable, and thus allow for a controlled release of BMPs by fine-tuning the mate-
rial degradation kinetics to match in vivo bone healing processes. Poly(lactic acid) 
(PLA) was an initial carrier to be used for BMP delivery, but it was ineffective due 
to the release of acidic degradation by-products that deactivate BMP. Subsequently, 
poly(lactic-co-glycolic acid) (PLGA) received particular attention because it com-
bines the absorptive stability of PLA with mechanical strength of polyglycolic acid 
(PGA) and offers tunable biodegradability by varying the proportion of the two 
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components. Poly(ethylene glycol) (PEG) is a bio-inert hydrophilic polymer that is 
versatile for hydrogel formation or for conjugating with biomolecules including 
growth factors, cell adhesion peptides, and enzymes for controlling matrix degrada-
tion (e.g., matrix metalloproteinase)[179, 230]. Because of its unique chemical 
structure (i.e., two hydroxyl end groups), PEG can be converted into other func-
tional groups to obtain a tunable physical state. This tunable state renders the PEG 
injectable and in situ cross-linkable either via a temperature-dependent liquid- 
semisolid transition [called thermosensitive polymers, such as polypropylene 
fumarate- co-ethylene glycol [14], poly-D,L-lactic acid-polyethylene glycol (PLA- 
PEG) block copolymers [85, 160]] or via in situ polymerization through chemical 
[e.g., poly(ethylene glycol) fumarate[179]] or photo-cross-linking mechanisms 
[e.g., poly(ethylene glycol) diacrylate [35, 228]]. Furthermore, synthetic polymers 
also provide higher mechanical properties (such as torsional strength) than the bio-
polymers which are crucial for healing large bone defects. However, additional 
materials for intervention may hinder BMP release from the bulk or alter BMP 
molecular integrity and thus compromise its bioactivity. Nonetheless, these materi-
als are often bio-inert and lacking bone-inducing effects. This has led to the devel-
opment of injectable, in situ setting ceramic cements as BMP delivery carriers.
Ceramic cements, such as calcium phosphate or hydroxyapatite, have been 
shown to have high binding affinity for BMP molecules [108, 206], thus making 
them suitable carriers for effective delivery of BMP in addition to their well-known 
osteoconductive and osteoinductive effects. The osteoinductive effect of calcium 
phosphate is beneficial as BMP devices as currently formulated must be used at 
very high concentrations to be effective [55]. In fact, ceramic pastes incorporated 
with rhBMP-2 showed to accelerate healing of critical-sized bone defects in pre-
clinical large animals, such as canine [42] and nonhuman primate [170]. Bioactive 
glass is another promising bone-inducing biomaterial and delivery vehicle for 
BMPs due to its unique ability to bond to living bone and promote bone regenera-
tion [220]. It has been reported that BMPs can be covalently immobilized onto 
bioactive glass effectively via surface functionalization techniques such as silaniza-
tion [205] or physical absorption onto apatite coating formed on bioactive glass 
[123]. The benefits of injectable synthetic polymer and ceramic carriers for BMP 
delivery gave rise to the development of injectable composite carriers that were 
found to enhance bone formation and were linearly dependent on the amount of 
additional calcium phosphate powder in respect to the rhBMP-2/calcium phosphate 
ratio [84]. Nevertheless, lack of open-pore structures or low porosity of the hardened 
paste appears to be the major drawback of this delivery method, which may inter-
rupt BMP release kinetics and prevent ingrowth of surrounding tissues and the for-
mation of neo-tissues, thereby compromising or delaying bone formation. For this, 
injectable micro- or nanocarriers that are encapsulated or chemically immobilized 
with BMPs are developed to circumvent these drawbacks by providing a higher 
specific area for BMP release and interparticle open spaces for tissue growth. For 
instances, these injectable micro- or nanocarriers have been reported to be success-
fully made from PLGA [152], chitosan [125], silk fibroin [17], polycaprolactone 
[12], and calcium phosphate [208].
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Recently, carbon nanotube (CNT) was reported to be a promising biomaterial for 
bone tissue engineering [1]. In addition to the high mechanical strength, surface 
functionalizing the nanotube surface with BMPs was shown to be feasible and gave 
rise to controlled release of BMPs and accelerated chondrogenic and osteogenic 
differentiation of progenitor cells and in vivo bone formation [112]. Interestingly, an 
inhibitory effect of CNT was found on carboxylated CNT that showed to inhibit 
proliferation and differentiation of precursor cells which may be modulated via a 
SMAD-dependent BMP signaling pathway [113]. This indicates that further inves-
tigation is necessary to gain more insights into the biomedical applicability of CNT 
as BMP delivery system, in addition to the potential cytotoxicity effects due to intra-
cellular accumulation of CNTs [62] or generation of reactive oxygen species [151].
4.3   Solid Porous Scaffolds for BMP- and Cell-Based ATMPs
Three-dimensional (3D) scaffolds play an important role in tissue regeneration by 
providing attachment sites, void spaces, as well as bioactive signals for cells to grow 
and differentiate into specific lineages. Specifically, it aims to provide a precise 
microenvironment for optimal expansion and control of differentiation of precursor 
cells that subsequently lead to 3D functional organ formation. Conventional tech-
niques are employed to produce 3D porous scaffolds in solid (e.g., salt leaching, 
porogen sacrifice, and gas foaming), fibrous (e.g., electrospinning), and micro-
spheres (e.g., water-to-oil emulsion and droplet generation). These scaffolds could 
act as efficient drug delivery systems, delivering BMP homogeneously in a three- 
dimensional manner which is an important criterion to elicit bone formation in all 
or a targeted direction.
It is known that the clinical efficacy of recombinant human BMPs (rhBMPs) will 
depend on the carrier system used to ensure an effective delivery of adequate protein 
concentrations to the defect site [134]. Various modes of BMPs incorporation into the 
scaffolds have been developed and showed promising bone formation outcomes [20]. 
The most convenient method is by physical absorption onto porous scaffold, whereby 
BMPs are randomly impregnated within the delivery matrix without  chemical bond-
ing. However, physical absorption will lead to an initial burst release of BMPs. BMPs 
can also be incorporated into the porous scaffolds by entrapment within a hydropho-
bic polymeric matrix during scaffold production in order to obtain an extended period 
of BMP release. The risk of BMP protein denaturation and loss of bioactivity could 
arise due to temperature changes during the production process or pH shift due to 
material degradation. Hydrogel scaffolds made from extracellular matrix (e.g., hyal-
uronic acid, heparin sulfate, heparin proteoglycans) or charged polymers (e.g., chito-
san, alginate, or synthetic polyelectrolytes) are interesting biomaterials for BMP 
delivery, attributed to the strong affinity of BMPs or via ion complexation binding of 
BMPs with the biomaterials. Modification of surface chemistries of the porous scaf-
folds for immobilization of BMPs via covalent binding showed to be more promising 
than any nonspecific immobilization methods. This immobilization can be achieved 
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by either modifying the chemical backbone structures of the biomaterials or grafting 
functional groups that are specific for BMP molecules onto the surface of scaffolds. 
Alternatively, BMP protein with a domain of specific binding to the scaffolds can be 
produced due to the great versatility of the recombinant technology nowadays. 
Therefore, chemical immobilization of BMPs has provided feasibility to develop 
“smart” BMP-releasing scaffolds which guaranteed precise dosing and control over 
BMP release such as via cell-mediated activity [114], light [93], temperature [115], 
and pH changes [51]. Incorporation of other essential biological cues to enhance cell 
adhesion and growth on the porous scaffolds is an attractive approach to enhance the 
biological functions of the porous scaffolds. For instance, hyaluronic acid scaffold 
was reported to be superior over collagen gel as carrier for a gradual and sustainable 
release of functional rhBMP-2 [86], and covalent grafting of fibronectin fragments 
within the hyaluronic acid structures enhanced cell attachment and spreading, as well 
as improved quality of ectopic bone formation [88].
Besides biochemical signals between cells, physical parameters of the scaffolds are 
shown to exhibit significant effects on tissue formation starting at the single-cell level. 
Indeed, the behavior of stem cells or osteochondro-progenitors is strongly influenced 
by the geometrical features of scaffold pores. It is reported that small pore sizes 
(<500 μm in diameter) gave rise to lower scaffold permeability (than the bigger pore 
size; >500 μm in diameter), thus, resulting in significantly higher in vitro cell seeding 
efficiency but faster occlusion of the pores that blocked further cell growth [201]. In 
vivo, subcutaneous implantation of porous hydroxyapatite scaffolds (in combination 
with BMP-2) with pore sizes of 300–400  μm resulted in highest bone formation, 
whereas pore size of 90–120 μm gave rise to cartilage tissues, a phenomenon that was 
dependent on the vascular invasion [99, 199]. Additionally, the pore curvature imposed 
active mechanical forces that influenced the speed of cell growth, which resulted in a 
curvature-driven cell growth pattern that was associated with distinct patterns of actin 
organization and alignment [63, 95]. Interestingly, a study using sheep critical-sized 
bone defects showed that the scaffold architecture directed bone tissue organization 
through structural guidance and load transfer, while BMP stimulation accelerated bone 
formation without  altering the bone tissue microstructure at different length scales [29]. 
These findings indicated important implications toward the understanding of natural 
processes of bone defect healing and bone remodeling, as well as important clues for 
designing optimum 3D porous scaffolds [158].
Advances in 3D additive manufacturing (e.g., selective laser melting/sintering, 
fused deposition modeling, and solid free-form fabrication) have opened up the fea-
sibility to fabricate synthetic 3D microenvironments that mimic the regulatory char-
acteristics of natural extracellular matrices (ECMs) and ECM-bound growth factors 
in addition to the indispensable biological and physical criteria required on the scaf-
folds to warrant success during in vitro 3D culture and in vivo tissue formation [10]. 
Since BMPs are delicate proteins that are vulnerable to temperature and pH, it is of 
utmost importance that the employed 3D printing technology must not compromise 
the bioactivity of the incorporated BMPs; otherwise incorporation of BMPs is to be 
carried out on the surface of scaffolds after the production process via the aforemen-
tioned methods. Examples of 3D-printed porous scaffolds for BMP delivery include 
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Table 4 Types of biomaterials as potential BMP-related ATMPs: advantages and disadvantages
Types of biomaterials Advantages Disadvantages
A. Non-ceramic based
1. Natural-origin
(e.g., collagen, gelatin, 
fibrin, chitin/chitosan, 
alginate, hyaluronic 
acid, and agarose)
Biocompatible and biodegradable
Allows clinical malleability 
according to defect geometry and 
application (injectable, moldable 
putty like, sponges, hydrogels, 
3D-printed porous scaffolds)
Simple incorporation of BMP into 
the biomaterials
Risk of disease transmission 
and immunogenic
Limited sources and 
impurities contamination
Low mechanical properties
2. Synthetic polymers 
(e.g., polylactic acid, 
polylactic- glycolic 
acid, polycaprolactone, 
polyethylene oxide, 
polyethylene glycol, 
polypropylene, 
polyvinyl alcohol)
Biocompatible, biodegradable, and 
free of risk of disease transmission
Available by mass production via 
chemical synthesis
Tunable chemical and material 
properties for specific BMP release 
and material degradation profiles to 
match bone healing
Allows cells encapsulation and 
chemical immobilization of 
biomolecules to enhance biological 
activity
No or low intervention with BMP 
bioactivity
Presence in hydrogel form or 
3D-printed porous scaffolds to allow 
patient-customary implant design
Potential deactivation of 
BMP and immunogenic due 
to acidic degradation 
products
Insufficient mechanical 
strength for load-bearing 
applications
No bone-inducing property 
thus required high BMP 
dosage to achieve the desired 
therapeutic effect
B. Ceramic-based biomaterials
1. An organic animals’ 
bone granules
Confers superior osteoinductivity 
due to high similarity of chemical 
composition and structure to native 
bone
Biocompatible, biodegradable, and 
non-immunogeni
Ideal delivery vehicle for BMPs due 
to high binding affinity and material 
degradation
Possess physiological calcium and 
phosphate ions release kinetics for 
stimulating bone formation
Risk of zoonosis transmission 
and limited sources
Limited sources and 
impurities contamination and 
toxicity
Inconsistent bone formation 
outcomes due to the variation 
in animals and production 
factors
(continued)
polymer-based scaffolds [e.g., polycaprolactone [225]], hydrogels [e.g., PEG [164, 
175]], ceramics [e.g., biphasic calcium phosphate [186]], and metallic [e.g., titanium 
alloys [227]]. This technology has potential to fulfill the needs for engineering an 
efficient upscale production of ATMPs with quality attributes of high controllability 
and reproducibility. Table 4 shows a summary of different types of biomaterials and 
their advantages and disadvantages as potential BMP-related ATMPs.
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Table 4 (continued)
Types of biomaterials Advantages Disadvantages
2. Calcium carbonate 
(e.g., corals, egg shells)
Alternative resources and cost 
effectiv
Can be synthesized into calcium 
phosphate-based apatites
Risk of zoonosis 
transmission and impurities 
contamination
3. Calcium phosphate 
and bioactive glasses 
(e.g., hydroxyapatite, 
tricalcium phosphate, 
biphasic CaP, 
octacalcium phosphate, 
calcium pyrophosphate, 
dicalcium phosphate)
Widely used as synthetic bone 
substitutes due to its excellent 
osteoconductivity and 
osteoinductivity
Possess higher biomechanical 
strength than polymer- or hydrogel-
based biomaterials
Allows fine-tuning of the material 
degradation and BMP release 
kinetics
Synthetic and thus free of risk of 
disease transmission and impurities 
contamination
High affinity for BMPs binding, and 
unlimited availability
Can be formed into paste-like or 
3D-printed porous scaffolds
Rigid, brittle, and requires 
fixators in load-bearing 
application
May induce adverse 
inflammatory responses and 
osteoclastic resorption
May interfere BMP signaling 
activation
C. Metals (e.g., 
titanium- based, 
cobalt-chromium, 
zirconium, stainless 
steel, tantalum, 
magnesium alloys)
Biocompatible and offers excellent 
mechanical strength
Can be produced into implants with 
desired defect geometry and 
3D-printed porous scaffolds
Allows surface immobilization of 
BMPs for controlled delivery 
applications
Bio-inert and thus not interfering 
with BMP effects
Provide immediate mechanical 
support and mobility to patients
Nonbiodegradable and 
requires surgical intervention 
due to implant wear off
Risk of metal toxicity or 
chronic inflammatory 
responses
D. Composites made 
from the above 
biomaterials
(e.g. Composites of 
CaP with collagen, 
hydrogels or polymers; 
Hydrogel or CaP-
coated of collagen, 
polymer or metallic 
sponges or scaffolds)
Improved mechanical strength, 
osteoconductivity and 
osteoinductivity
Higher versatility and flexibility in 
fine-tuning the material properties 
and bioactivities
Offers higher technological 
flexibility for different clinical 
implications and demands
Improved BMPs delivery as 
compared to single material  
delivery
Lack of technological tools 
as well as knowledge on the 
BMP-material-host 
interactions for developing an 
ideal biomaterial that 
optimally elicits bone 
regeneration based on BMP 
technology
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5  Toward ATMP Combining BMP and Cells
Since powerful “raw materials” are now available in clinical grade such as BMPs, 
CE-approved smart biomaterials, and GMP-manufactured cell suspensions such as 
BMSCs or periosteal-derived cell populations, we have set out to produce combina-
tions of these that exceed the biological potency of the single products such as 
BMPs or biomaterials only. These combination products are envisioned to be of use 
for large bone defects in compromised environments, with sick tissues, lack of stem 
or progenitor cells close by, and where the implant needs to drive semiautonomously 
the process of tissue formation and integration despite an unfavorable environment. 
This may be in genetic diseases such as NF1, where the periosteum compartment is 
simply ineffective or an aging patient with diabetes and osteoporosis or 
osteomalacia.
The search for these optimal combination products is quite challenging and 
should be based on the principles of developmental engineering as a concept of 
“in vitro biomimetics of in vivo tissue development” [109, 110]. In short, the 
design of cell-based products should integrate the concepts of developmental 
biology, so that the behavior of networks of genes, proteins, or cells that govern 
the unfolding of developmental processes could be related to the design param-
eters. In addition, it is necessary to involve new methodologies such as design of 
experiment (DoE) approach to determine the optimal setup for each design 
parameters. We recently conducted a full-factor DoE analysis of bone formation 
capacity induced by ATMPs with different calcium phosphate scaffolds, BMP 
loading dosage, and cell seeding dosage (Ji and Kerkhofs et al. in preparation). 
Our data indicates that indeed the proper dosage combinations of BMPs and cells 
seeded on specific scaffolds can generate skeletal tissue intermediates with 
higher bone-forming potency, improved bone quality, and more active contribu-
tion from donor cells, exceeding these of smart biomaterials only with growth 
factors or cells.
To turn this into robust manufacturing processes, new enabling technologies 
such as perfusion bioreactors in combination with biosensors are required. Such 
setup provides several advantages for a manufacturing pipeline, including (1) direct 
cell-cell and cell-extracellular matrix interaction, (2) direct control over shear 
stress development, and (3) accurate sensor readouts at the outlet of the bioreac-
tors. It also helps to develop structurally defined and functionally effective complex 
3D-engineered constructs at the patient scale using scale-out strategies [146]. In 
addition, noninvasive imaging will be necessary to further tailor the quality charac-
teristics of specific stem cell culture as well as for more complex 3D TE construct 
culture [146]. Furthermore, regulatory requirements are evolving for these novel 
3D products and their manufacturing processes. Therefore, the effective bioreac-
tor systems with incorporation of multiple sensors would provide information-
rich processes for the manufacturing of TE products that could meet regulatory 
demands [146].
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6  Preclinical Evaluation of ATMPs Combining BMP 
and Cells
BMP, stem cells, and biomaterials can be considered as “raw materials” in the 
development of ATMPs. Although recent progress has been achieved in BMP pro-
duction, (stem) cell culture and expansion as well as new biomaterials fabrication, 
respectively, the translation of knowledge from in vitro model systems to in vivo 
and upscaling to the clinical setting is still challenging. Therefore, it is necessary to 
use sequential animal model systems to fully understand the biological performance 
of these devices in a living organism before translation into the clinics can be made. 
The following section will focus on animal models suitable for preclinical evalua-
tion of BMP-/cell-based ATMPs.
6.1   Ectopic Model
Particularly for bone regeneration, the ectopic model provides a relatively con-
trolled and clean system to evaluate the in vivo de novo bone formation capacity of 
human cell-based ATMPs. Therefore, this is suitable as a first-line screening model 
to identify the biocompatibility, toxicity, and bioactivity of ATMPs. The three most 
commonly used ectopic models are subcutaneous, intramuscular thigh, and under- 
the- kidney capsule implantation [169]. Despite the advantages of the ectopic model, 
the differences in the inflammatory, immunological, biochemical, and mechanical 
environment between ectopic and orthotopic locations are distinct, which greatly 
affects the bone-forming process induced by the ATMP. For instance, Levi et al. 
[111] showed that adipose-derived stem cells successfully ossified a critical size 
defect. However, the same implants did not result in significant bone formation in 
the ectopic model.
Another concern comes from the different tissue responses between immune- 
deficient and immune-competent animals upon ATMP implantation. Liu et al. [116] 
showed that hydroxyapatite tricalcium phosphate (HA-TCP) scaffolds combined 
with mouse BMSCs were much less osteoinductive in syngeneic immune- competent 
mice than immune-deficient mice when implanted ectopically. Furthermore, recipi-
ent T lymphocytes were found to inhibit bone formation in immune-competent mice 
via inflammatory factors such as IFN gamma and TNF alpha. In a different study, 
gene expression profiles of the implants showed that T lymphocyte differentiation 
and activation gene markers were upregulated in immune-competent mice in com-
parison to immune-deficient mice [21]. Our recent data confirmed that BMP-6- mouse 
PDCs combined implants induced bone formation in the ectopic model in immune-
deficient mice, but failed to do so when tested in immune-competent mice (Fig. 3).
On the other hand, it is well known that a proper inflammatory response is an 
essential part of the natural bone healing process [135]. Consequently, modulation 
of inflammation in ATMP implantation is of utmost importance. More recent 
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a
Immune-deficient mouse Immune-competent mouse
b
Fig. 3 Mouse PDC-mediated bone formation in immune-deficient and immune-competent mouse. 
HE staining of tissue explants from immune-deficient mouse (a) and immune-competent mouse 
(b) 6 weeks after subcutaneous implantation of BMP-6-coated scaffolds with syngeneic mouse 
PDCs (scale bar = 100 μm, B bone, BM bone marrow)
emphasis has been given to the modulation of the inflammatory reaction toward 
improved bone regeneration. New strategies based on surface modifications of bio-
materials, coupling of anti-inflammatory drugs to biomaterials, delivery of growth 
factors, and infusion of MSCs have been explored [48, 117, 153, 176]. For instance, 
it was reported that Nel-like molecule-1 (NELL-1), a protein first identified for its 
osteoinductive properties in craniosynostosis patients, could suppress the BMP-2- 
induced inflammatory reaction in  vivo [176]. Furthermore, systemic infusion of 
MSCs had a positive effect on reducing IFN gamma and TNF alpha and promoted 
bone formation when scaffolds combined with MSCs were implanted ectopically in 
immune-competent mice [117]. Nevertheless, there are no methods that generate 
the same amount of bone in immune-competent mice compared to immune- 
deficient mice without concerns regarding its clinical safety. Therefore, further 
studies are required to fully understand the interaction between the immune system 
and bone tissue formation, providing new insights for successful application of 
bone tissue engineering strategies.
6.2   Orthotopic Model
Orthotopic models refer to studies in which the bone is formed in its correct and 
relevant anatomical location. These can be applied in different species to fulfill spe-
cific research questions, which can be categorized as (1) understanding of mecha-
nism of action and (2) clinical upscaling, feasibility, safety, and efficacy prediction. 
For instance, to understand the mechanism underlying bone formation, small 
rodents such as mice and rats are preferred due to availability of immune-deficient 
animals for xenograft-based experiment [169]. For clinical translation, the defect 
should be upscaled in a clinically relevant setting with critical size, which is “above 
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the threshold size intraosseous defect dimensions that will not heal spontaneously 
during the lifetime of the animal” [166]. Therefore, large animals are more appro-
priate. Table 5 summarizes the advantages and disadvantages when applying ortho-
topic models in different animal species.
From a surgical point of view, orthotopic models can be categorized as (1) cal-
varial defect and (2) segmental long-bone defect, which has different critical sizes 
Table 5 Orthotopic models in different animals with critical size
Animal Advantages Disadvantages
Calvarial 
defect
Segmental 
long-bone 
defect References
Rodents 
(mice 
and rat)
Easy to perform 
surgery
Availability of 
Immunodeficient 
animals
Availability of 
specific disease-
target gene 
knockout animal
Relatively thicker 
and fewer trabeculae 
than humans
Mice and rat do not 
have Haversian 
system
Periosteum in rats 
and is well 
vascularized, hence 
improving bone 
healing
Mice: 
5 mm 
diameter
Rat: 8 mm 
diameter
Mice: 
0.4 cm in 
the radius, 
0.5 cm in 
the femur
Rat: 1 cm in 
the radius, 
0.4–0.5 cm 
in the tibia, 
0.5-1 cm in 
the femur
[13, 32, 
203, 204]
Dog Tractable nature
Similar bone 
mineral density to 
humans
Higher rate of solid 
bony fusion when 
compared to 
humans
Low nonunion rates
Ethical issues and 
negative public 
perception
Significant 
inter-animal 
variations due to 
breed diversity
N/A 0.3–2.5 cm 
in the 
radius
2–2.5 cm 
in the ulna
2.1–7 cm 
in the 
femur
[74, 154]
Sheep Docile animals 
with easy outdoor 
housing
Similar body 
weight to humans
Hind limb 
anatomy similar to 
humans
Dimension of long 
bones suitable for 
human implants
Higher trabecular 
bone density than 
humans
Late skeletal 
maturity,, with 
Haversian 
remodeling at 
7–9 years of age
N/A 3–3.5 cm 
in the tibia
2.5 cm in 
the femur
[74, 203, 
221]
Pig Better social 
acceptance
Bone mineral 
density and 
healing similar to 
humans
Hind limb anatomy 
is different to 
humans
Rapid growth rate
Difficult handling
N/A 2.5–3 cm 
in the 
radius
[74, 203, 
221]
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depending on location, age, and animal species (Table 5). The calvarial defect model 
provides a good non-loading-bearing bone-healing environment with relative bio-
logical inertness due to poor blood supply and limited access of bone marrow, which 
is thought to resemble the atrophic mandibular bone in humans. Furthermore, it 
provides a good simultaneous environment to study the intramembranous ossifica-
tion and allows the establishment of a uniform, reproducible, and standardized 
defect. The standard rodent calvarial bone defect is typically created by using a 
trephine drill that makes a circular defect in the cranial skeleton on the midline 
[189]. It is suggested that the sagittal suture and the dura mater underlying the 
defect have to be carefully protected during the surgery which is important for the 
cranial skeleton healing. Furthermore, the filling materials should be strong and suf-
ficiently resistant to avoid the dilation of brain tissue beneath the defect [78]. The 
rodent models are the first-choice models for in vivo testing of regenerative and/or 
therapeutic approaches but are not suited to the establishment of long-term studies 
and immediately translation to a clinical setting.
Segmental long-bone defects allow researchers to test and understand the tis-
sue formation destined for long-bone healing with mechanical loading and in 
upscaled treatment modalities for clinical application. The creation of segmental 
long-bone defects is usually done in an osteotomy approach, which utilizes a drill 
or saw to surgically remove the required length of the bone from a predetermined 
site, producing a consistent defect in all animal species. After filling the defect, it 
can be internally fixed with either bone plates or intramedullary rods [74] or by 
external fixation such as the Ilizarov fixation technique. In addition, we recently 
developed a sheep segmental tibial defect bone model, which provides additional 
insights on the handling, safety, feasibility, and upscaling possibilities of different 
regenerative treatments. However, also in this large-animal bone defect model, 
discussions still remain in defining a critical size defect being the one that does 
not achieve spontaneous healing during the lifetime of the animal. Therefore, the 
design of a large-animal model has to be stringent, where factors such as the age 
of the animal, the defect size, and the fixation material used will have a significant 
impact. Moreover, this phenomenon of spontaneous bone regeneration, which can 
occur in a large-animal bone model and thus can interfere with a regenerative 
treatment applied in the defect, can be seen as “background noise” and can there-
fore lead to over-enthusiastic conclusions about the actual effect of a regenerative 
treatment (Fig. 4).
7  Cell-Based Combination Products: Challenges 
and Perspectives
Bone fracture healing is essential for the quality of life and even survival. Therefore, 
a natural tightly regulated cascade of cellular and molecular events has evolved in 
evolution leading to a successful healing process allowing the individual to survive 
and resume normal function within 6–10 weeks. However, the bone-healing process 
gets delayed and leads to a nonunion or nonhealing fracture when the defects are too 
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large or comprising conditions such as infection and diseased bones arise. In the 
animal world, a nonunion or nonhealing fracture results inevitably to death. In 
humans we have the challenge to try to obtain healing by other means in an attempt 
to restore function and thus independence of the patient.
Novel solutions have been developed in the past decades, including the discovery 
of antibiotics to fight infection, new surgical techniques and instrumentation to 
obtain full immobilization, and bone distraction osteogenesis as developed by 
Ilizarov [67, 75]. In addition, impressive progress in our knowledge on the cell and 
developmental biology of bone as well as fracture healing has triggered the discov-
ery of new growth and differentiation factors such as BMPs and the development of 
smart biomaterials. This in turn has led to an unprecedented number of opportuni-
ties and strategies to enhance bone healing.
Despite all these stellar developments, there are still quite some clinical chal-
lenges, and growing in number, also due to the aging population. These include 
large bone defects in compromised environments in the patient with comorbidities 
such as cardiovascular disease, diabetes, osteoporosis, and osteomalacia. In addition, 
large bone defects as a result of revisions of joint prostheses are becoming a real 
challenge in daily clinical practice.
In view of this, we need to turn to more sophisticated strategies, combining and 
improving all the powerful tools and insights that nature has provided us. 
Opportunities include the use of (stem) cell technologies, the development of 
more sophisticated growth factor formulations, and the optimization of biologi-
cally relevant scaffolds that are enhancing the biological processes and not just 
sitting there as an inert material. Ultimately, the dream is to combine all these to 
create living tissue intermediates or provisional tissues that upon implantation 
steer the healing process in the right direction, also called developmental engi-
neering [109, 110]. Growing knowledge and insights on both materials engineer-
ing and cell biology is crucial to implement the essential natural temporal and 
spatial complexity within the synthetic microenvironment that recapitulates 
developmental and healing processes of cell proliferation, differentiation, and tis-
sue morphogenesis [120].
Fig. 4 Animal models for preclinical evaluation of regenerative treatment possibilities for bone 
regeneration. (a) Ectopic model in rodents is mainly used for biocompatibility and bioactivity 
screening. Orthotopic defect with Ilizarov fixation technique in mouse (b) and rabbits (c) is usually 
used to study the mechanism of action underlying the tissue formation. The upscaled orthotopic 
defect in sheep (d) is useful for clinical translation
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To produce these living tissues “of the shelf,” we have serious manufacturing 
challenges. In combination with robust in  vitro culture technology that mimics 
closely the in vivo “biological chamber,” upscaled tissue engineering constructs or 
ATMPs could be engineered into sufficiently pre-differentiated tissue intermediates 
that are directly recognized by the microenvironment and readily initiate the cas-
cade of bone regeneration. In this perspective, bioreactors with sophisticated online 
monitoring systems tracking all relevant cellular metabolic profiles and culture 
environment readouts become critical assets. Novel enabling technologies such as 
biosensors will be instrumental for industrial manufacturing modular processes for 
cell-based combination products.
In conclusion, we believe the era of regenerative medicine has just started. First- 
generation BMP and stem cell technologies have demonstrated that in the postnatal 
environment, one can successfully enhance the healing of damaged tissues by reca-
pitulating the principles of developmental tissue formation. The stage is set; it is up 
to us to take on the challenge for the second-generation products that lead to the 
creation of living replacement body parts.
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